These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19593512)

  • 1. Adjuvant therapy of breast cancer - bisphosphonates.
    Saarto T
    Cancer Treat Res; 2009; 151():163-77. PubMed ID: 19593512
    [No Abstract]   [Full Text] [Related]  

  • 2. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
    [No Abstract]   [Full Text] [Related]  

  • 4. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
    Hadji P
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
    Jonat W
    MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
    [No Abstract]   [Full Text] [Related]  

  • 7. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
    Garreau JR; Delamelena T; Walts D; Karamlou K; Johnson N
    Am J Surg; 2006 Oct; 192(4):496-8. PubMed ID: 16978958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of bone loss induced by aromatase inhibitors.
    Gnant M
    Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors for breast cancer prevention.
    Cuzick J
    J Clin Oncol; 2005 Mar; 23(8):1636-43. PubMed ID: 15755971
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault RL
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
    Diel I; Aebi S
    Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing the risk of osteoporosis in women with a history of early breast cancer.
    Ravdin PM
    Oncology (Williston Park); 2004 Oct; 18(11):1385-90, 1393; discussion 1394. PubMed ID: 15609468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
    Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
    Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitor-associated bone loss.
    Bryce J; Bauer M; Hadji P
    Oncol Nurs Forum; 2011 May; 38(3):273-6. PubMed ID: 21531678
    [No Abstract]   [Full Text] [Related]  

  • 19. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density in breast cancer: when to intervene?
    Gralow JR
    J Clin Oncol; 2007 Aug; 25(22):3194-7. PubMed ID: 17577014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.